natgillin/translations-raw huggingface dataset:
In the two other studies, Rasagiline ratiopharm was given as ‘add-on' to patients with later stage disease who were already being treated with levodopa, and compared with placebo and another medicine entacapone (also used as add-ons). 
Kahes teises uuringus kasutati Rasagiline ratiopharmi lisaravimina hilisemas staadiumis haigusega patsientidele, kes juba võtsid levodopat, ning seda võrreldi platseebo ja entakapooniga, mida samuti kasutati lisaravimina.
It is not intended to provide practical advice on how to use Rasagiline ratiopharm. 
Hindamisaruandes ei anta Rasagiline ratiopharmi kasutamise praktilisi nõuandeid.
There should be at least 14 days between stopping treatment with Rasagiline ratiopharm and starting treatment with another monoamine-oxidase inhibitor or with pethidine. 
Pärast Rasagiline ratiopharmi ravi lõppu peab ootama vähemalt 14 päeva, enne kui tohib alustada ravi muu monoaminoksüdaasiinhibiitori või petidiiniga.
Rasagiline ratiopharm is a medicine used to treat adults with Parkinson's disease (a progressive brain disorder that causes shaking, slow movement and muscle stiffness). 
Rasagiline ratiopharm on ravim, mida kasutatakse Parkinsoni tõvega (progresseeruv ajuhäire, mis põhjustab värisemist, liigutuste aeglust ja lihasjäikust) täiskasvanute raviks.
Rasagiline ratiopharm has been shown in three studies, involving 1,563 patients, to be effective in both relieving the symptoms of Parkinson's disease and in reducing the time patients spend in their ‘off' periods. 
Kolmes 1563 patsiendiga uuringus tõestati, et Rasagiline ratiopharm on efektiivne nii Parkinsoni tõve sümptomite leevendamisel kui ka liikumisraskustega seisundiga perioodide lühendamises.
Why is Rasagiline ratiopharm approved? 
Miks Rasagiline ratiopharm heaks kiideti?
For practical information about using Rasagiline ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate Rasagiline ratiopharmi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
In both studies, patients taking Rasagiline ratiopharm spent an average of around one hour less in the ‘off' state than those taking placebo. 
Mõlemas uuringus olid Rasagiline ratiopharmi uuringurühma patsiendid keskmiselt ligikaudu ühe tunni võrra vähem liikumisraskustega seisundis kui platseeborühma patsiendid.
Rasagiline ratiopharm contains the active substance rasagiline. 
Rasagiline ratiopharm sisaldab toimeainet rasagiliini.
Other information about Rasagiline ratiopharm 
Muu teave Rasagiline ratiopharmi kohta
Rasagiline ratiopharm can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients who are having ‘fluctuations' towards the end of the period between levodopa doses. 
Rasagiline ratiopharmi tohib kasutada ainsa ravimina või lisaks levodopale (samuti Parkinsoni tõve ravim) patsientidel, kellel esineb levodopa annuste vahelise aja lõpus seisundite vaheldumist.
Patients with mild liver problems should use Rasagiline ratiopharm with caution and should stop treatment if their liver problems get worse. 
Rasagiline ratiopharmi kasutamisel kergete maksaprobleemidega patsientidel peab olema ettevaatlik ning maksaprobleemide süvenemisel tuleb ravi peatada.
For more information about treatment with Rasagiline ratiopharm, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Rasagiline ratiopharmiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about. 
Seisundite vaheldumine on seotud levodopa toime vähenemisega, mil patsiendil hakkavad liikumisvõimega ja liikumisraskustega seisundid järsku vahelduma.
For the full list of all side effects and restrictions with Rasagiline ratiopharm, see the package leaflet. 
Rasagiline ratiopharmi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
What are the risks associated with Rasagiline ratiopharm? 
Mis riskid Rasagiline ratiopharmiga kaasnevad?
For the full list of all side effects reported with Rasagiline ratiopharm, see the package leaflet. 
Rasagiline ratiopharmi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
How does Rasagiline ratiopharm work? 
Kuidas Rasagiline ratiopharm toimib?
Rasagiline ratiopharm must not be used with other monoamine oxidase inhibitors including medicines and herbal preparations without prescription such as St John's wort (used to treat depression). 
Rasagiline ratiopharmi ei tohi kasutada koos teiste monoaminoksüdaasiinhibiitoreid sisaldavate ravimite ja taimsete käsimüügiravimitega, näiteks naistepunaga (teatud depressiooniravim).
It is not recommended for patients with moderate liver problems. 
Rasagiline ratiopharmi ei ole soovitatav kasutada ka mõõdukate maksaprobleemidega patsientidel.
What benefits of Rasagiline ratiopharm have been shown in studies? 
Milles seisneb uuringute põhjal Rasagiline ratiopharmi kasulikkus?
Rasagiline ratiopharm must not be used in patients who have severe problems with their liver. 
Raske maksapuudulikkusega patsiendid ei tohi Rasagiline ratiopharmi kasutada.
How is Rasagiline ratiopharm used? 
Kuidas Rasagiline ratiopharmi kasutatakse?
Cortacare received a marketing authorisation valid throughout the EU on 27 August 2018. 
Cortacare müügiluba, mis kehtib kogu Euroopa Liidus, anti 27. augustil 2018.
Further information on Cortacare can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Lisateave Cortacare kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This reduces swelling, redness and itching. 
See vähendab turset, punetust ja sügelust.
Cortacare EMA/406528/2018 
EMA/406528/2018
Other information about Cortacare 
Muu teave Cortacare kohta
The European Medicines Agency concluded that, in accordance with EU requirements, Cortacare has been shown to be comparable to Cortavance. 
Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud Cortacare võrreldavus ravimiga Cortavance.
As for every medicine, the company provided studies on the quality of Cortacare. 
Nagu iga ravimi korral, esitas ettevõte Cortacare kvaliteedi uuringud.
Cortacare is sprayed onto the affected area of skin at a distance of about 10 cm once daily for a week. 
Cortacaret pihustatakse haigestunud nahapiirkonnale ligikaudu 10 cm kauguselt kord ööpäevas ühe nädala jooksul.
What is Cortacare and what is it used for? 
Mis on Cortacare ja milleks seda kasutatakse?
How has Cortacare been studied? 
Kuidas Cortacaret uuriti?
Cortacare (hydrocortisone aceponate) 
Cortacare (hüdrokortisoonatseponaat)
An overview of Cortacare and why it is authorised in the EU 
Ravimi Cortacare ülevaade ja Euroopa Liidus heakskiitmise põhjused
Therefore, the Agency's view was that, as for Cortavance, the benefit of Cortacare outweighs the identified risk and it can be authorised for use in the EU. 
Seetõttu on amet arvamusel, et nagu ka Cortavance korral, ületab Cortacare kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
Because Cortacare is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Et Cortacare on hübriidravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Cortavance, and do not need to be repeated for Cortacare. 
Võrdlusravimiga Cortavance on juba tehtud toimeaine heakskiidetud kasutamisviisi kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Cortacare korrata.
Cortacare is a corticosteroid veterinary medicine used to treat inflamed and itchy skin conditions in dogs. 
Cortacare on kortikosteroidist veterinaarravim, mida kasutatakse koerte põletikuliste ja sügelusega nahaseisundite raviks.
The hydrocortisone in Cortacare is in a special chemical form (di-ester) so the medicine is able to get into the outer layer of the skin and remain there for longer. 
Ravimis Cortacare sisalduv hüdrokortisoon on sellises keemilises vormis (diester), mis võimaldab ravimil tungida naha väliskihti ja püsida seal pikema aja vältel.
The active substance in Cortacare, hydrocortisone aceponate, is a corticosteroid or ‘steroid' which acts in the skin cells by stopping the release of chemicals which are involved in inflammation. 
Cortacare toimeaine hüdrokortisoonatseponaat on kortikosteroid ehk steroid, mis toimib naharakkudes, peatades põletiku tekkes osalevate keemiliste ainete vabanemise.
For more information about using Cortacare, see the package leaflet or contact your veterinarian or pharmacist. 
Kui vajate ravimiga Cortacare toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
Safety information has been included in the summary of product characteristics and the package leaflet for Cortacare, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Cortacare ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
Cortacare is a ‘hybrid medicine'. 
Cortacare on hübriidravim.
This means that it is similar to a ‘reference medicine' containing the same active substance. 
See tähendab, et Cortacare on sarnane võrdlusravimiga, mis sisaldab sama toimeainet.
It contains the active substance hydrocortisone aceponate. 
Ravim sisaldab toimeainena hüdrokortisoonatseponaati.
Two sprays is sufficient to treat an area of skin 10 cm by 10 cm. Care should be taken to avoid spraying the eyes of the dog. 
Kahest pihustuskorrast piisab 10×10 cm suuruse nahapiirkonna raviks.
What are the benefits and risks of Cortacare? 
Milles seisneb Cortacare kasulikkus ja mis riskid ravimiga kaasnevad?
This makes the medicine more effective at low doses in skin conditions. 
Selle tulemusena on ravim nahaseisundite ravis efektiivsem väikestes annustes.
composition of Cortacare is the same as the reference medicine and when sprayed onto the skin, the active substance in both products is expected to be absorbed in the same way. 
Seda ei olnud vaja, sest Cortacare koostis on sama kui võrdlusravimil ja nahale pihustamisel on toimeaine eeldatav imendumine mõlemal ravimil ühesugune.
There was no need for ‘bioequivalence' studies to investigate whether Cortacare is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Bioekvivalentsust, st kas Cortacare imendub organismis samamoodi kui võrdlusravim, et saavutada toimeaine sarnane sisaldus veres, ei olnud vaja uurida.
How is Cortacare used? 
Kuidas Cortacaret kasutatakse?
Why is Cortacare authorised in the EU? 
Cortacare Euroopa Liidus heakskiitmise põhjused
Cortacare is available as a spray and can only be obtained with a prescription. 
Cortacaret turustatakse spreina ja see on retseptiravim.
The reference medicine for Cortacare is Cortavance. 
Cortacare võrdlusravim on Cortavance.
The precautions are the same as for the reference medicine since Cortacare is a hybrid medicine. 
Kuna Cortacare on hübriidravim, siis on meetmed samad mis võrdlusravimi korral.
How does Cortacare work? 
Kuidas Cortacare toimib?
Ref. EMEA/727640/2009 EMEA/H/C/1057 
London, 19. november 2009 Viide: EMA/727640/2009 EMEA/H/C/1057
What is Mersarex? 
Mis on Mersarex?
The main measure of effectiveness was the number of patients who were cured. 
Efektiivsuse põhinäitaja oli tervenenud patsientide arv.
Following the CHMP's opinion, it usually takes around two months for the European Commission to issue a decision on this opinion. 
Pärast komitee arvamuse andmist kulub Euroopa Komisjonil arvamuse kohta otsuse tegemiseks ligikaudu kaks kuud.
The company presented results from two main studies involving 991 adults with complicated infections of the skin and soft tissues. 
Ettevõte esitas kahe põhiuuringu tulemused, milles osales 991 naha ja pehmekudede tüsistunud nakkustega täiskasvanut.
There were also concerns that the medicine may cause side effects affecting the heart (such as QTc interval prolongation, an alteration of the electrical activity of the heart) and the liver. 
Ettevaatlikkust tekitas ka asjaolu, et ravim võib põhjustada kõrvalnähtusid, mis mõjutavad südant (nagu QTc-intervalli pikenemine, südame elektrilise aktiivsuse muutus) ja maksa.
Complicated means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect the response to treatment. 
„Tüsistunud“ tähendab, et nakkust on raske ravida, sest see on kas levinud sügavale nahaalustesse kudedesse, vaja võib olla kirurgilist ravi või patsiendil on muu haigus, mis võib ravivastust mõjutada.
Around half of the patients were treated with Mersarex, while the others were treated with linezolid (another antibiotic). 
Umbes pooled patsientidest said ravi Mersarexiga, ülejäänud aga linesoliidiga (samuti antibiootikum).
The letter from the company notifying the CHMP of the withdrawal of the application is available here. 
Ettevõtte kiri, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, on avaldatud siin.
The study looked at whether Mersarex given for up to 14 days was as good as linezolid. 
Uuringus jälgiti, kas kuni 14 päeva jooksul manustatud Mersarex oli sama efektiivne kui linesoliid.
The CHMP also noted that some bacteria already show a level of resistance to the antibiotic even before it is in general use. 
Inimravimite komitee märkis ka, et juba enne ravimi üldkasutusse võtmist on täheldatud teatud bakteritüvede osalist resistentsust antibiootikumi suhtes.
The application was at day 181 when the company withdrew. 
Taotluse menetlemine oli kestnud 180 päeva, kui ettevõte võttis taotluse tagasi.
By blocking the action of dihydrofolate reductase, the medicine was expected to slow down the growth and spread of the bacteria. 
Eeldati, et dihüdrofolaadi reduktaasi toime blokeerimisega aeglustab ravim bakterite kasvu ja levikut.
The CHMP was of the opinion that the results did not show that Mersarex was as good as the comparator medicine and that there were insufficient data from clinical studies to justify the dosage proposed by the company. 
Inimravimite komitee arvas, et uuringutulemused ei tõendanud, et Mersarex on sama efektiivne kui võrdlusravim, ja et kliiniliste uuringute andmed ei olnud piisavad, et õigustada ettevõtte väljapakutud annuse kasutamist.
On 21 October 2009, Arpida A/S officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Mersarex, for the treatment of adults with complicated skin and soft tissue infections. 
oktoobril 2009 teatas Arpida A/S ametlikult inimravimite komiteele oma soovist võtta tagasi naha ja pehmekudede tüsistunud nakkuste raviks täiskasvanutel kasutada kavatsetud ravimi Mersarex müügiloa taotlus.
Bacteria need this protein to produce the active form of folic acid, which they need to multiply. 
Bakterid kasutavad seda valku paljunemiseks vajaliku foolhappe aktiivse vormi sünteesimiseks.
What are the consequences of the withdrawal for patients in clinical trials or compassionate use programmes using Mersarex? 
Kuidas mõjutab tagasivõtmine praegu Mersarexi kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Mersarex could not have been approved for the treatment of complicated infections of the skin and the soft tissues. 
Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjuseid ettevaatlikkuseks ning oli esialgsel seisukohal, et Mersarexile ei või anda naha ja pehmekudede tüsistunud nakkuste raviks müügiluba.
The active substance in Mersarex, iclaprim, is an antibiotic of the group ‘dihydrofolate reductase inhibitors'. 
Mersarexi toimeaine iklapriim on dihüdrofolaadi reduktaasi inhibiitorite rühma kuuluv antibiootikum.
The company informed the CHMP that there are no patients currently using Mersarex in clinical trials or compassionate use programmes. 
Ettevõte teatas inimravimite komiteele, et Mersarexi ei kasutata praegu üheski kliinilises uuringus ega eriloaga kasutamise programmis.
Mersarex is a concentrate for solution for infusion (drip into a vein). 
Mersarex on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
Questions and answers on the withdrawal of the marketing authorisation application for Mersarex iclaprim 
Teave müügiloa taotluse tagasivõtmise kohta Mersarex iklapriim21.
It was expected to work by blocking the action of a bacterial protein called dihydrofolate reductase. 
Eeldati, et see blokeerib dihüdrofolaadi reduktaasi (bakterivalgu) toime.
The effects of Mersarex were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Mersarexi toimet muude katsetega.
Mersarex was expected to be used to treat complicated infections of the skin and the ‘soft tissues' below the skin. 
Mersarexi kavatseti kasutada naha ja nahaaluste pehmekudede tüsistunud nakkuste raviks.
What was Mersarex expected to be used for? 
Milleks kavatseti Mersarexi kasutada?
How was Mersarex expected to work? 
Milline on Mersarexi eeldatav toime?
It contains the active substance iclaprim. 
Ravim sisaldab toimeainena iklapriimi.
Treatment initiation pack: 14 tablets + 14 tablets + 14 tablets + 14 tablets 
Ravi stardipakend: 14 tabletti + 14 tabletti + 14 tabletti + 14 tabletti
1 bottle + 1 measuring cup + 1 oral syringe + 1 adaptor 
1 pudel + 1 mõõtetops + 1 suusüstal + 1 adapter
Oral use bottle (glass) 
10 mg/ml Siirup pudel (klaas)
Pharmaceutical form 
Ravimi nimetus
Content Package size 
Ravimi nimetus Tugevus Ravimivorm Loomaliik Manustamisviis Pakend
Target species 
Tugevus Ravimivorm Loomaliik Manustamisviis Pakend
London, 21 August 2008 Doc. 
London, 21. august 2008 Dok.
Ref. EMEA/402553/2008 
viide EMEA/402553/2008
International non-proprietary name (INN): ketoprofen 
Rahvusvaheline mittekaubanduslik nimetus (INN): ketoprofeen
The main measure of effectiveness was the change in the severity of pain after 12 weeks of treatment. 
Peamine tõhususe näitaja oli valu tugevuse muutus pärast 12-nädalast ravi.
Following the CHMP's opinion, it usually takes around two months for the European Commission to grant a license. 
Pärast komitee arvamust kulub Euroopa Komisjonil müügiloa andmiseks ligikaudu kaks kuud.
The effectiveness of Diractin was studied in one main study involving 866 patients with osteoarthritis of the knee. 
Diractini tõhusust uuriti ühes põhiuuringus, milles osales 866 põlve osteoartriidiga patsienti.
The study compared the effectiveness of three different doses of Diractin (25 mg, 50 mg and 100 mg twice a day) with that of placebo (a dummy treatment). 
Uuringus võrreldi Diractini kolme annuse (25 mg, 50 mg ja 100 mg kaks korda päevas) tõhusust platseebo (näiva ravimi) tõhususega.
What is Diractin? 
Mis on Diractin?
Therefore, at the time of the withdrawal, the CHMP was of the opinion that any benefits of Diractin did not outweigh the identified risks. 
Seepärast oli inimravimite komitee tagasivõtmise ajal arvamusel, et Diractini kasulikkus ei ületa tuvastatud riske.
It was to be available as a gel containing 22.9 mg of ketoprofen per gram of gel. 
Seda oleks turustatud geelina, mis sisaldab 22,9 mg ketoprofeeni ühe grammi geeli kohta.
On 23 July 2008, IDEA AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Diractin, for the treatment of the symptoms of inflammation and pain associated with osteoarthritis. 
23. juulil 2008 teatas IDEA AG ametlikult inimravimite komiteele oma soovist võtta tagasi osteoartriidiga seotud põletikusümptomite ja valu raviks kasutada kavatsetud ravimi Diractin müügiloa taotlus.
The CHMP was concerned that the effectiveness of Diractin had not been sufficiently demonstrated in the single main study: compared with placebo, Diractin did not reduce pain levels to an extent that would be relevant for patients. 
Inimravimite komitee ettevaatlikkuse põhjuseks oli see, et ainus põhiuuring ei olnud Diractini tõhusust piisavalt tõendanud: võrreldes platseeboga ei vähendanud Diractin valu raskusastet patsientide jaoks olulisel määral.
In Diractin gel, the ketoprofen is contained in special, small, fatty particles (called ‘Transfersomes') that are expected to carry the ketoprofen through the skin and release it deep below the skin, where the inflammation in osteoarthritis occurs. 
Diractini geelis sisaldub ketoprofeen spetsiaalsetes väikestes rasvaosakestes („transfersoomides“), mis viivad ketoprofeeni eelduste kohaselt läbi naha ja vabastavad selle sügaval naha all, kus esineb osteoartriidi korral põletik.
What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Diractin? 
Kuidas mõjutab tagasivõtmine praegu Diractini kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
By reducing the production of prostaglandins, Diractin is expected to reduce the inflammation and pain caused by osteoarthritis. 
Prostaglandiinide tootmise vähendamisel leevendab Diractin eelduste kohaselt osteoartriidi põhjustatud põletikku ja valu.
Diractin is a medicine that contains the active substance ketoprofen. 
Diractin sisaldab toimeainet ketoprofeeni.
Questions and answers on the withdrawal of the marketing application for Diractin 
Teave müügiloa taotluse tagasivõtmise kohta Diractin
No compassionate use programmes with Diractin are being conducted. 
Diractini eriloaga kasutamise programme läbi ei viida.
The effects of Diractin were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Diractini toimet muude katsetega.
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Diractin 
Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjuseid ettevaatlikkuseks ning oli esialgsel
What was Diractin expected to be used for? 
Milleks kavatseti Diractini kasutada?
Diractin was expected to be used to treat the symptoms of inflammation and pain associated with osteoarthritis (a condition that causes swelling and pain in the joints). 
Diractini kavatseti kasutada osteoartriidiga (seisund, mis põhjustab liigeste turset ja valu) seotud põletikusümptomite ja valu raviks.
How is Diractin expected to work? 
Milline on Diractini eeldatav toime?
It is expected to work by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process. 
See blokeerib prostaglandiine tootvat ensüümi tsüklooksügenaasi.
The active substance in Diractin, ketoprofen, is a non-steroidal anti-inflammatory drug (NSAID). 
Diractini toimeaine ketoprofeen on mittesteroidne põletikuvastane ravim (MSPVR).
could not have been approved for the treatment of the symptoms of inflammation and pain associated with osteoarthritis. 
arvamusel, et Diractinile ei või anda müügiluba kasutamiseks osteoartriidiga seotud põletikusümptomite ja valu ravis.
- if you are a child (less than 12 years old). 
− kui Te olete laps (noorem kui 12-aastane);
Date of first authorisation: 19 February 2009 Date of renewal: 19 February 2014 
Müügiloa esmase väljastamise kuupäev: 19. veebruar 2009 Müügiloa uuendamise kuupäev: 19. veebruar 2014